Targeted Gene Panel Sequencing for Early-onset Inflammatory Bowel Disease and Chronic Diarrhea

  • Britt-Sabina Petersen
  • Dietrich August
  • Renate Abt
  • Moudjahed Alddafari
  • Lida Atarod
  • Safa Baris
  • Hemant Bhavsar
  • Florian Brinkert
  • Mary Buchta
  • Alla Bulashevska
  • Ronnie Chee
  • Ana I Cordeiro
  • Naghi Dara
  • Gregor Dückers
  • Aisha Elmarsafy
  • Natalie Frede
  • Nermeen Galal
  • Patrick Gerner
  • Erik-Oliver Glocker
  • Sigune Goldacker
  • Jutta Hammermann
  • Peter Hasselblatt
  • Zuzana Havlicekova
  • Katrin Hübscher
  • Milos Jesenak
  • Neslihan E Karaca
  • Elif Karakoc-Aydiner
  • Mahboubeh M Kharaghani
  • Sara S Kilic
  • Ayca Kiykim
  • Christoph Klein
  • Christian Klemann
  • Robin Kobbe
  • Daniel Kotlarz
  • Martin W Laass
  • T Ronan Leahy
  • Mehrnaz Mesdaghi
  • Sally Mitton
  • João F Neves
  • Birol Öztürk
  • Luis F Pereira
  • Jan Rohr
  • Jessica L R Restrepo
  • Gunda Ruzaike
  • Nadia Saleh
  • Suranjith Seneviratne
  • Ebru Senol
  • Carsten Speckmann
  • Daniel Tegtmeyer
  • Paul Thankam
  • Jutte van der Werff Ten Bosch
  • Horst von Bernuth
  • Sebastian Zeissig
  • Yvonne Zeissig
  • Andre Franke
  • Bodo Grimbacher

Related Research units

Abstract

BACKGROUND: In contrast to adult-onset inflammatory bowel disease (IBD), where many genetic loci have been shown to be involved in complex disease etiology, early-onset IBD (eoIBD) and associated syndromes can sometimes present as monogenic conditions. As a result, the clinical phenotype and ideal disease management in these patients often differ from those in adult-onset IBD. However, due to high costs and the complexity of data analysis, high-throughput screening for genetic causes has not yet become a standard part of the diagnostic work-up of eoIBD patients.

METHODS: We selected 28 genes of interest associated with monogenic IBD and performed targeted panel sequencing in 71 patients diagnosed with eoIBD or early-onset chronic diarrhea to detect causative variants. We compared these results to whole-exome sequencing (WES) data available for 25 of these patients.

RESULTS: Target coverage was significantly higher in the targeted gene panel approach compared with WES, whereas the cost of the panel was considerably lower (approximately 25% of WES). Disease-causing variants affecting protein function were identified in 5 patients (7%), located in genes of the IL10 signaling pathway (3), WAS (1), and DKC1 (1). The functional effects of 8 candidate variants in 5 additional patients (7%) are under further investigation. WES did not identify additional causative mutations in 25 patients.

CONCLUSIONS: Targeted gene panel sequencing is a fast and effective screening method for monogenic causes of eoIBD that should be routinely established in national referral centers.

Bibliographical data

Original languageEnglish
ISSN1078-0998
DOIs
Publication statusPublished - 12.2017
PubMed 28930861